M I Danilevskii, O V Zakharova, N N Skaletskiy, Yu B Basok, S A Roumiantsev, A V Lyundup
{"title":"Cell Therapy for Type 1 Diabetes Mellitus: a Review of Clinical Trials.","authors":"M I Danilevskii, O V Zakharova, N N Skaletskiy, Yu B Basok, S A Roumiantsev, A V Lyundup","doi":"10.1007/s10517-025-06444-5","DOIUrl":null,"url":null,"abstract":"<p><p>The article provides a review of cell therapy strategies for type 1 diabetes mellitus that are closest to approval by regulatory authorities and implementation in clinical practice. The data from contemporary clinical trials studying the safety and efficacy of cell technologies in the treatment of type 1 diabetes mellitus are presented. The main approaches to replacement and immunomodulatory cell therapy are defined. The results of using insulin-producing cells, regulatory T lymphocytes, tolerogenic dendritic cells, and mesenchymal stromal cells are described. Non-pharmacological strategies for preventing the rejection of allogeneic cell products are considered. The limitations and possibilities of cell therapy strategies for type 1 diabetes mellitus are analyzed.</p>","PeriodicalId":9331,"journal":{"name":"Bulletin of Experimental Biology and Medicine","volume":" ","pages":"112-122"},"PeriodicalIF":0.6000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin of Experimental Biology and Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10517-025-06444-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/19 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
The article provides a review of cell therapy strategies for type 1 diabetes mellitus that are closest to approval by regulatory authorities and implementation in clinical practice. The data from contemporary clinical trials studying the safety and efficacy of cell technologies in the treatment of type 1 diabetes mellitus are presented. The main approaches to replacement and immunomodulatory cell therapy are defined. The results of using insulin-producing cells, regulatory T lymphocytes, tolerogenic dendritic cells, and mesenchymal stromal cells are described. Non-pharmacological strategies for preventing the rejection of allogeneic cell products are considered. The limitations and possibilities of cell therapy strategies for type 1 diabetes mellitus are analyzed.
期刊介绍：
Bulletin of Experimental Biology and Medicine presents original peer reviewed research papers and brief reports on priority new research results in physiology, biochemistry, biophysics, pharmacology, immunology, microbiology, genetics, oncology, etc. Novel trends in science are covered in new sections of the journal - Biogerontology and Human Ecology - that first appeared in 2005.
World scientific interest in stem cells prompted inclusion into Bulletin of Experimental Biology and Medicine a quarterly scientific journal Cell Technologies in Biology and Medicine (a new Russian Academy of Medical Sciences publication since 2005). It publishes only original papers from the leading research institutions on molecular biology of stem and progenitor cells, stem cell as the basis of gene therapy, molecular language of cell-to-cell communication, cytokines, chemokines, growth and other factors, pilot projects on clinical use of stem and progenitor cells.
The Russian Volume Year is published in English from April.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
